Literature DB >> 25088193

Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.

B Bardot1, R Bouarich-Bourimi1, J Leemput1, V Lejour1, A Hamon1, L Plancke1, A G Jochemsen2, I Simeonova1, M Fang1, F Toledo1.   

Abstract

Mdm4, a protein related to the ubiquitin-ligase Mdm2, is an essential inhibitor of tumor suppressor protein p53. In both human and mouse cells, the Mdm4 gene encodes two major transcripts: one encodes the full-length oncoprotein (designated below as Mdm4-FL), whereas the other, resulting from a variant splicing that skips exon 6, encodes the shorter isoform Mdm4-S. Importantly, increased Mdm4-S mRNA levels were observed in several human cancers, and correlated with poor survival. However, the role of Mdm4-S in cancer progression remains controversial, because the Mdm4-S protein appeared to be a potent p53 inhibitor when overexpressed, but the splice variant also leads to a decrease in Mdm4-FL expression. To unambiguously determine the physiological impact of the Mdm4-S splice variant, we generated a mouse model with a targeted deletion of the Mdm4 exon 6, thereby creating an obligatory exon skipping. The mutant allele (Mdm4(ΔE6)) prevented the expression of Mdm4-FL, but also led to increased Mdm4-S mRNA levels. Mice homozygous for this allele died during embryonic development, but were rescued by a concomitant p53 deficiency. Furthermore in a hypomorphic p53(ΔP/ΔP) context, the Mdm4(ΔE6) allele led to p53 activation and delayed the growth of oncogene-induced tumors. We next determined the effect of Mdm4(+/ΔE6) heterozygosity in a hypermorphic p53(+/Δ31) genetic background, recently shown to be extremely sensitive to Mdm4 activity. Mdm4(+/ΔE6) p53(+/Δ31) pups were born, but suffered from aplastic anemia and died before weaning, again indicating an increased p53 activity. Our results demonstrate that the main effect of a skipping of Mdm4 exon 6 is not the synthesis of the Mdm4-S protein, but rather a decrease in Mdm4-FL expression. These and other data suggest that increased Mdm4-S mRNA levels might correlate with more aggressive cancers without encoding significant amounts of a potential oncoprotein. Hypotheses that may account for this apparent paradox are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25088193     DOI: 10.1038/onc.2014.230

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.

Authors:  Yunyuan V Wang; Mathias Leblanc; Norma Fox; Jian-Hua Mao; Kelsey L Tinkum; Kurt Krummel; Dannielle Engle; David Piwnica-Worms; Helen Piwnica-Worms; Allan Balmain; Kenneth Kaushansky; Geoffrey M Wahl
Journal:  Genes Dev       Date:  2011-07-01       Impact factor: 11.361

2.  The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.

Authors:  Lei Huang; Zheng Yan; Xiaodong Liao; Yuan Li; Jie Yang; Zhu-Gang Wang; Yong Zuo; Hidehiko Kawai; Miriam Shadfan; Suthakar Ganapathy; Zhi-Min Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

3.  MDM2 and MDMX in cancer and development.

Authors:  Jean-Christophe Marine
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

4.  Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.

Authors:  Heather A Steinman; Kathleen M Hoover; Marilyn L Keeler; Arthur T Sands; Stephen N Jones
Journal:  Oncogene       Date:  2005-11-24       Impact factor: 9.867

5.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

6.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

Authors:  Franck Toledo; Kurt A Krummel; Crystal J Lee; Chung-Wen Liu; Luo-Wei Rodewald; Mengjia Tang; Geoffrey M Wahl
Journal:  Cancer Cell       Date:  2006-04       Impact factor: 31.743

7.  Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.

Authors:  M Fang; I Simeonova; B Bardot; V Lejour; S Jaber; R Bouarich-Bourimi; A Morin; F Toledo
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

8.  Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth.

Authors:  Heather A Steinman; Hayla K Sluss; Arthur T Sands; German Pihan; Stephen N Jones
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

9.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

10.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.

Authors:  Andrea Prodosmo; Simona Giglio; Sonia Moretti; Francesca Mancini; Flavia Barbi; Nicola Avenia; Giusy Di Conza; Holger J Schünemann; Lorenza Pistola; Vienna Ludovini; Ada Sacchi; Alfredo Pontecorvi; Efisio Puxeddu; Fabiola Moretti
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

View more
  21 in total

1.  PRMT1-p53 Pathway Controls Epicardial EMT and Invasion.

Authors:  Olan Jackson-Weaver; Nicha Ungvijanpunya; Yuan Yuan; Jiang Qian; Yongchao Gou; Jian Wu; Hua Shen; Yibu Chen; Meng Li; Stéphane Richard; Yang Chai; Henry M Sucov; Jian Xu
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

Review 2.  RNA Splicing and Disease: Animal Models to Therapies.

Authors:  Matías Montes; Brianne L Sanford; Daniel F Comiskey; Dawn S Chandler
Journal:  Trends Genet       Date:  2018-11-19       Impact factor: 11.639

3.  [Construction of an adenovirus vector expressing engineered splicing factor for regulating alternative splicing of YAP1 in neonatal rat cardiomyocytes].

Authors:  Y Li; Q Zhao; X Song; J Song
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

4.  Loss of TAF8 causes TFIID dysfunction and p53-mediated apoptotic neuronal cell death.

Authors:  Farrah El-Saafin; Maria I Bergamasco; Yunshun Chen; Rose E May; Prabagaran Esakky; Soroor Hediyeh-Zadeh; Mathew Dixon; Stephen Wilcox; Melissa J Davis; Andreas Strasser; Gordon K Smyth; Tim Thomas; Anne K Voss
Journal:  Cell Death Differ       Date:  2022-03-31       Impact factor: 12.067

5.  Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

Authors:  Michael Dewaele; Tommaso Tabaglio; Karen Willekens; Marco Bezzi; Shun Xie Teo; Diana H P Low; Cheryl M Koh; Florian Rambow; Mark Fiers; Aljosja Rogiers; Enrico Radaelli; Muthafar Al-Haddawi; Soo Yong Tan; Els Hermans; Frederic Amant; Hualong Yan; Manikandan Lakshmanan; Ratnacaram Chandrahas Koumar; Soon Thye Lim; Frederick A Derheimer; Robert M Campbell; Zahid Bonday; Vinay Tergaonkar; Mark Shackleton; Christine Blattner; Jean-Christophe Marine; Ernesto Guccione
Journal:  J Clin Invest       Date:  2015-11-23       Impact factor: 14.808

6.  Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.

Authors:  Kathryn T Bieging-Rolett; Alyssa M Kaiser; David W Morgens; Anthony M Boutelle; Jose A Seoane; Eric L Van Nostrand; Changyu Zhu; Shauna L Houlihan; Stephano S Mello; Brian A Yee; Jacob McClendon; Sarah E Pierce; Ian P Winters; Mengxiong Wang; Andrew J Connolly; Scott W Lowe; Christina Curtis; Gene W Yeo; Monte M Winslow; Michael C Bassik; Laura D Attardi
Journal:  Mol Cell       Date:  2020-11-05       Impact factor: 17.970

Review 7.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

8.  Zmat3 splices together p53-dependent tumor suppression.

Authors:  Kathryn T Bieging-Rolett; Laura D Attardi
Journal:  Mol Cell Oncol       Date:  2021-04-29

9.  p53 downregulates the Fanconi anaemia DNA repair pathway.

Authors:  Sara Jaber; Eléonore Toufektchan; Vincent Lejour; Boris Bardot; Franck Toledo
Journal:  Nat Commun       Date:  2016-04-01       Impact factor: 14.919

10.  Mdm4: don't judge an isoform by its mRNA levels!

Authors:  Boris Bardot; Franck Toledo
Journal:  Aging (Albany NY)       Date:  2015-10       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.